RIPK1-IN-35

RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC50 of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C) -induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis[1].

Product Specifications

UNSPSC

12352005

Target

Necroptosis; RIP kinase

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

O=C(NC1=NNC(C2=CC=C3N(CCOC3=C2)C(CC4=C(C=CC(OC(F)F)=C4)F)=O)=C1)C5=NN(C([2H])([2H])[2H])C(C=C5)=O

Molecular Formula

C26H18D3F3N6O5

Molecular Weight

557.50

References & Citations

[1]Tao Q, et al. Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease. J Med Chem. 2025 Oct 23;68 (20) :21766-21785.